Background. Brain natriuretic peptide (BNP), as a cardiac hormone, is
expressed together with atrial natriuretic peptide (ANP) in the ventri
cles in congestive heart failure. However, the ventricular expression
of BNP in hypertrophic cardiomyopathy (HCM) with normal systolic funct
ion is still unclear. Methods and Results. The study population consis
ted of 39 HCM patients with asymmetric septal hypertrophy and 10 contr
ol subjects without any specific cardiac disease. Eleven cases of HCM
were obstructive (HOCM), and the other 28 cases were nonobstructive (H
NCM). All of these patients had a normal ejection fraction. Immunohist
ochemical analysis of endomyocardial biopsy specimens with specific mo
noclonal antibodies showed BNP immunoreactivity in the HOCM group (5/1
0,50%) but not in the HNCM group (0/22) or in control subjects (0/5).
In HOCM, left ventricular end-diastolic pressure was significantly hig
her in the BNP-positive patients than the BNP-negative patients. Histo
logical changes such as myocardial fiber disarray, hypertrophy of myoc
ytes, and fibrosis were greater in BNP-positive patients than BNP-nega
tive patients in HCM. However, the expression had no significant relat
ion with other clinical parameters. The elevation of the BNP plasma le
vel versus control subjects was marked in both HOCM (85-fold) and HNCM
(23-fold). By contrast, the elevation of the ANP plasma level versus
control subjects was mild in HOCM (5.7-fold) and HNCM (4.2-fold). The
ratio of BNP level to ANP level was higher in HOCM (4.16) than in HNCM
(1.46) and control subjects (0.28), and it was higher than the ratio
previously reported for severe congestive heart failure (1.72). Conclu
sions. These findings suggest that BNP is expressed in the ventricular
myocytes of HCM with normal systolic function. In HOCM, ventricular e
xpression of BNP may be augmented in response to both obstruction and
diastolic dysfunction.